Trigger finger, medically designated as stenosing tenosynovitis, is a highly common hand condition characterized by painful clicking, snapping, or locking of the digit during flexion and extension. The condition arises from a size mismatch between the flexor tendons and the surrounding osteofibrous tunnel (pulley system), most frequently at the level of the first annular (A1) pulley. Left unmanaged, trigger finger can lead to fixed flexion contractures of the proximal interphalangeal (PIP) joint, resulting in permanent hand dysfunction. Treatment protocols focus on conservative management, including rest, orthotic splinting, corticosteroid injections, and surgical release for refractory cases.
Anatomy and Pathophysiology
The flexor tendons of the hand—the flexor digitorum superficialis (FDS) and flexor digitorum profundus (FDP)—glide smoothly inside a synovial sheath. This sheath is held close to the phalanges by a series of retinacular pulleys (annular and cruciform pulleys) that prevent “bowstringing” during finger flexion. The A1 pulley, located at the level of the metacarpophalangeal (MCP) joint, is the primary site of pathology. Repetitive friction, mechanical loading, or systemic micro-inflammation causes thickening, hypertrophy, and metaplasia of the A1 pulley. Simultaneously, a reactive nodule or swelling forms on the flexor tendon. When the finger flexes, the tendon nodule passes proximally through the thickened A1 pulley. Upon extension, the nodule becomes trapped under the distal edge of the pulley, causing a painful “pop” or “snap” as it is forced through, or locking the finger in a flexed position.
Risk Factors and Clinical Presentations
Risk factors for developing stenosing tenosynovitis include:
- Repetitive Gripping: Occupations or hobbies involving repetitive manual tasking, power gripping, or prolonged tool use.
- Systemic Diseases: Diabetes mellitus is a major risk factor; diabetic patients have a higher incidence of multi-digit involvement and lower response rates to non-surgical treatment.
- Inflammatory Conditions: Conditions like rheumatoid arthritis involve systemic synovitis, which directly inflames the flexor tendon sheath.
- Co-existing Neuropathies: Trigger finger frequently co-occurs with other hand disorders, such as carpal tunnel syndrome, due to shared mechanical loading pathways in the hand and wrist.
Symptoms range from mild tenderness over the A1 pulley and pain with gripping, to a clicking sensation, a palpable nodule that moves with the tendon, and locking of the finger in a flexed position that must be manually straightened with the other hand.
💡 💡 Clinical Pearl: Splinting Compliance and Joint Biomechanics
Clinical studies demonstrate that splinting the MCP joint in neutral or slight extension (0 to 10 degrees) for 6 to 8 weeks reduces mechanical rubbing of the tendon nodule against the A1 pulley. This allows inflammation to resolve, avoiding the need for invasive injections in up to 50% of mild cases.
Management and Treatment Protocols
The management of trigger finger follows a progressive, evidence-based algorithm:
- Rest and Activity Modification: Avoiding activities requiring repetitive gripping or pinching to allow the local tendon sheath swelling to subside.
- Orthotic Splinting: Wearing a custom or commercial splint that restricts movement of the MCP joint while allowing full movement of the proximal and distal interphalangeal joints. This is worn continuously or at night for 6-8 weeks.
- Corticosteroid Injections: A local injection of a corticosteroid (e.g., triamcinolone) combined with a local anesthetic into the flexor tendon sheath at the A1 pulley. This is highly effective, resolving symptoms in up to 70-80% of patients. The steroid rapidly reduces inflammation, shrinking the tendon nodule and thickened pulley.
- Surgical A1 Pulley Release: For cases that fail to respond to one or two corticosteroid injections, or for digits that are locked in flexion, a minor surgical release is performed. Under local anesthesia, the surgeon makes a small incision over the MCP joint and divides the A1 pulley, allowing the tendon to glide without obstruction.
💡 Frequently Asked Questions (FAQ)
Q1: Why are cortisone injections for trigger finger less successful in patients with diabetes?
A1: Patients with diabetes often have underlying tissue changes, including collagen glycosylation, microvascular disease, and chronic, low-grade tissue stiffness. This alters the structure of the A1 pulley and tendon sheath, making them more resistant to the anti-inflammatory effects of steroids. Diabetic patients have a higher recurrence rate and are more likely to require surgical release.
Q2: How many cortisone injections can I receive for a trigger finger?
A2: Generally, a maximum of two injections per digit is recommended. If symptoms return after two injections, the likelihood of a third injection providing long-term relief is very low (less than 10-15%). Continuing to inject steroids can also weaken the tendon, increasing the risk of tendon rupture. In such cases, surgical release is the preferred option.
Q3: What are the risks of trigger finger surgery, and what is the recovery time?
A3: A1 pulley release is a highly successful outpatient procedure with a success rate exceeding 97-99%. Risks are rare but include infection, damage to the digital nerves (causing numbness), incomplete release, and temporary scar tenderness. Most patients can use their hand for light activities immediately, and full recovery occurs within 2 to 4 weeks.
📚 References & Sources
- Makkouk, A. H., et al. (2008). Trigger finger: etiology, evaluation, and treatment. Current Reviews in Musculoskeletal Medicine, 1(2), 92-96.
- Ferrara, P. E., et al. (2020). Conservative treatment of trigger finger: a systematic review. European Journal of Physical and Rehabilitation Medicine, 56(3), 306-316.